---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-059716"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:47:56.058306+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director

## Summary
- Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.
- No arrangements or transactions requiring disclosure under Item 404(a) were identified.
- Compensation includes $40k annual cash retainer and initial option for 27,500 shares; one-third vests immediately, remainder monthly over two years.
- Automatic annual option grants of 13,750 shares on each annual meeting date vest on one-year anniversary or next annual meeting.

## SEC filing metadata
- accession: 0001193125-26-059716
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/0001193125-26-059716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/artv-20250128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-059716
- JSON: https://secwatch.observer/filing/0001193125-26-059716.json
- Plain text: https://secwatch.observer/filing/0001193125-26-059716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.